Hard Lessons from Vytorin’s ‘Trial Out of Hell’
Since 2002, when the first patient was enrolled in the controversial Enhance trial of the cholesterol drug Vytorin, Dutch researcher John Kastelein had been looking forward to presenting the findings to a lecture hall packed with thousands of other heart doctors. Kastelein (pictured) finally got that chance yesterday in Chicago at the American College of Cardiology, but not until he had endured so many frustrating battles over the readiness of the data and how to analyze them that he called En
More: continued here